[英文調查報告書] Amgen：製藥企業分析報告

Abstract

Amgen operates in one business segment - human therapeutics and markets products in the areas of haematology, immunology, inflammation and oncology. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Amgen was incorporated in 1980 and is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics. Amgen operates in one business segment - human therapeutics and markets products in the areas of haematology, immunology, inflammation and oncology. Research and development efforts are focused on novel theraputics for the treatment of haematology, inflammation, oncology, metabolic disorders and neuroscience.

Current Growth Drivers

Since Amgen markets a small number of products, they are all very significant to the company. Three products in particular have shown strong sales growth in recent years:

Aranesp (darbepoetin alpha), a novel erythropoiesis stimulating protein, is a recombinant protein which stimulates the production of red blood cells. In 2005, Aranesp usage in US hospital dialysis clinics increased, reflecting a conversion from Epogen in the treatment of various causes of anaemia.
Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony stimulating factor and developed in collaboration with Roche. Neulasta has demonstrated continued market gains since its launch in 2002. This rise in sales can be attributed to an increased awareness of febrile neutropenia.
Enbrel (etanercept) is a soluble tumour necrosis factor which has potential in several inflammatory diseases mediated by excess TNF. Enbrel sales growth has benefited from its competitive profile and significant increases in the usage of biologics in both rheumatology and dermatology settings.

Principal Operating Results

Breaking News

EXECUTIVE SUMMARY

Introduction
- Current Growth Drivers
- Key Late-Stage Products
- Key Early-Stage Products
Financial Performance 2005
- Sales and Market Position
- Income
  - Sales, Costs and Operating Income, 2005
- Expenditure
  - Capital Expenditure
  - R&D Expenditure
  - R&D Expenditure and Capital Expenditure
- Divisional Performance
- Geographic Performance
  - Sales By Geographical Area
  - Sales By Geographic Area, 2005
  - Long-Lived Assets By Geographical Area
  - Product Sales By Geographical Area
  - Product Sales By Geographical Area
  - Aranesp Sales By Geographic Area
  - Neulasta/Neupogen Sales By Geographic Area
  - Enbrel Sales By Geographic Area
Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
Product / R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
- Discontinued R&D projects
  - LymphoCide
  - GDNF
  - Plenaxis
- Sales Forecast
- Sales of Major Products (2000A-2010E)
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas and Sales
Major Product Sales, 2005
R&D Pipeline
Haematology - Products
- Major Launched Products
- Aranesp/Nespo
  - Sales
  - Key Markets/Indications/Formulations
  - Further Development
  - Safety Issues
  - Patents
  - Lawsuit
  - Competitor Products
  - Sales Forecast
- Aranesp Sales (2000A-2010E)
  - Clinical Trial Results in Heart Failure
  - Clinical Trial Results in Myelodysplastic Syndromes
  - Clinical Trial Results in Chronic Kidney Disease
  - Clinical Trial Results - TREAT
- Epogen
  - Sales
  - Key Markets/Indications/Formulations
  - Patents
  - Lawsuits
  - TKT/sanofi-aventis
  - Roche
  - Generic Competition
  - Competitor Products
  - Sales Forecast
- Epogen Sales (2000A-2010E)
  - Clinical Trial Results
Haematology - R&D
- AMG 531
  - Clinical Trial Results
Haematology - Summary
- Growth Potential
- Limiting Factors
Immunology - Products
- Major Launched Products
- Neulasta
  - Sales
  - Key Markets/Indications/Formulations
  - Sales Forecast
- Neulasta Sales (2000A-2010E)
  - Clinical Trial Results
- Neupogen/Granulokine
  - Sales
  - Key Markets/Indications
  - Patents
  - Lawsuits
  - Genentech
  - Chugai
  - Generic Competition
  - Competitor Products
  - Sales Forecast
- Neupogen Sales (2000A-2010E)
- Infergen
  - Key Markets/Indications/Formulations
  - Further Development
  - Lawsuit
Immunology - Summary
- Growth Potential
- Limiting Factors
Inflammation - Products
- Major Launched Products
- Enbrel
  - Sales
  - Key Markets/Indications/Formulations
  - Patents
  - Lawsuit
  - Competitor Products
  - Sales Forecast
- Enbrel Sales (2000A-2010E)
  - Clinical Trial Results
  - Clinical Trial Results in Rheumatoid Arthritis
  - Clinical Trial Results in Juvenile Rheumatoid Arthritis
- Kineret
  - Key Markets/Indications/Formulations
  - Competitor Products
  - Clinical Trial Results
Inflammation - R&D
- AMG 108
- AMG 623
- AMG 714
- Denosumab
  - Clinical Trial Results
Inflammation - Summary
- Growth Potential
- Limiting Factors
Oncology - Products
- Kepivance
  - Further Development
  - Clinical Trial Results
- Novantrone
  - Key Markets/Indications/Formulations
  - Safety Issues
Oncology - R&D
- AMG 102
- AMG 386
- AMG 479
- AMG 655
- AMG 706
- AMG 951
- Panitumumab
  - Clinical Trial Results
Oncology - Summary
- Growth Potential
- Limiting Factors
Metabolic Disorders - R&D
- AMG 076
- AMG 221
Metabolic - Summary
Neuroscience - R&D
- AMG 403
- AMG 517
Neuroscience - Summary
Other - Products
- Sensipar/Mimpara
  - Key Markets/Indications
  - Further Development
Other - R&D
- AMG 009
- AMG 317

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

Abgenix Inc
- 26th July 2000
- 28th November 2000
- 9th January 2001
- 10th July 2001
- 14th October 2003
- 13th August 2004
- 13th January 2005
Array BioPharma Inc
- 3rd October 2000
- 14th January 2002
Biovitrum AB
- 21st October 2003
- 13th February 2006
Boehringer Ingelheim Pharma KG
- 5th November 1998
- 27th June 2000 and 3rd June 2002
Cambridge Antibody Technology Ltd (CAT)
- 1st December 2000
- 21st May 2001
- 8th January 2002
- 24th December 2003
Celltech Group plc
- 17th May 2002
Eli Lilly
- 16th December 1999
- 7th November 2001
- 12th November 2002
Genmab A/S
- 17th May 1999
- 8th October 2001
- 1st July 2003
- 16th September 2003
GlaxoSmithKline
- 6th August 1998
Human Genome Sciences Inc (HGS)
- 9th January 2006
Infinity Pharmaceuticals Incorporated
- 8th January 2004
InterMune Inc
- 15th June 2001
- 28th November 2005
Isis Pharmaceuticals Inc
- 13th December 2001
- 3rd January 2002
- 14th August 2002
- 10th February 2003
Johnson & Johnson
- September 1985
Kirin Brewery Co Ltd/ Kirin-Amgen
- 1994
- July 1996
Medarex Inc
- 12th January 1999
- May 1999
- 23rd September 1999
- 4th November 2003
- 29th November 2004
- 24th February 2005
NeoGenesis Pharmaceuticals Inc
- 4th August 2003
NPS Pharmaceuticals Inc
- 18th March 1996
- 8th March 2004
- 9th August 2004
Orion Corporation
- 16th December 2003
Regeneron Pharmaceuticals Inc
- 31st August 1990
- 21st September 1994
- 16th April 1996
Roche
- Genentech agreement
- 8th June 1999
- 15th April 2002
- 23rd June 2005
- 26th January 2006
- Roche agreement
- 14th April 1997
- 1st June 1999
- May 2002
SkyePharma Plc
- 4th April 2000
Wyeth
- 25th September 1997
ZymoGenetics Inc
- 23rd January 2003
- 20th May 2004
Licensing
Co-Promotion/Co-Marketing

Amgen：製藥企業分析報告

Amgen: Performance, Products, Pipeline and Potential

Abstract

Current Growth Drivers

Table of Contents

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIAL PERFORMANCE

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

APPENDIX 4 - INFRASTRUCTURE

APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES

APPENDIX 6 - PRODUCT INDEX